Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain

Jijun J. Xu, Philippe Diaz, Fanny Astruc-Diaz, Suzanne Craig, Elizandro Munoz, Mohamed Naguib

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

BACKGROUND: Cannabinoid receptor 2 (CB2) agonists have recently gained attention as potential therapeutic targets in the management of neuropathic pain. In this study, we characterized the pharmacological profile of the novel compound N′-[(3Z)-1-(1-hexyl)-2-oxo-1,2-dihydro-3H-indol-3- ylidene]benzohydrazide (MDA19), a CB2 agonist. METHODS: We used radioligand binding assays and multiple in vitro functional assays at human and rat CB1 and CB2 receptors. The effects of MDA19 in reversing neuropathic pain were assessed in various neuropathic pain models in rats and in CB2+/+ and CB2-/- mice. RESULTS: MDA19 displayed 4-fold-higher affinity at the human CB2 than at the human CB1 receptor (Ki = 43.3 ± 10.3 vs 162.4 ± 7.6 nM) and nearly 70-fold-higher affinity at the rat CB 2 than at the rat CB1 receptor (Ki = 16.3 ± 2.1 vs 1130 ± 574 nM). In guanosine triphosphate (GTP)γ[35S] functional assays, MDA19 behaved as an agonist at the human CB1 and CB2 receptors and at the rat CB 1 receptor but as an inverse agonist at the rat CB2 receptor. In 3′,5′-cyclic adenosine monophosphate (cAMP) assays, MDA19 behaved as an agonist at the rat CB1 receptor and exhibited no functional activity at the rat CB2 receptor. In extracellular signal-regulated kinases 1 and 2 activation assays, MDA19 behaved as an agonist at the rat CB2 receptor. MDA19 attenuated tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and CB2+/+ mice but not in CB2-/- mice, indicating that CB2 receptors mediated the effects of MDA19. MDA19 did not affect rat locomotor activity. CONCLUSIONS: We found that MDA19 exhibited a distinctive in vitro functional profile at rat CB2 receptors and behaved as a CB1/CB2 agonist in vivo, characteristics of a protean agonist. MDA19 has potential for alleviating neuropathic pain without producing adverse effects in the central nervous system.

Original languageEnglish (US)
Pages (from-to)99-109
Number of pages11
JournalAnesthesia and analgesia
Volume111
Issue number1
DOIs
StatePublished - Jul 2010

Fingerprint

Cannabinoids
Neuralgia
Cannabinoid Receptors
Pharmacology
Ligands
Cannabinoid Receptor CB1
Cannabinoid Receptor Agonists
Therapeutics
N'-((3Z)-1-(1-hexyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene)benzohydrazide
Spinal Nerves
Radioligand Assay
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Hyperalgesia
Locomotion
Paclitaxel
Guanosine Triphosphate
Cyclic AMP
Ligation
Central Nervous System

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. / Xu, Jijun J.; Diaz, Philippe; Astruc-Diaz, Fanny; Craig, Suzanne; Munoz, Elizandro; Naguib, Mohamed.

In: Anesthesia and analgesia, Vol. 111, No. 1, 07.2010, p. 99-109.

Research output: Contribution to journalArticle

Xu, Jijun J. ; Diaz, Philippe ; Astruc-Diaz, Fanny ; Craig, Suzanne ; Munoz, Elizandro ; Naguib, Mohamed. / Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. In: Anesthesia and analgesia. 2010 ; Vol. 111, No. 1. pp. 99-109.
@article{7068cdd2790e47bf8d67e2b601ac7577,
title = "Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain",
abstract = "BACKGROUND: Cannabinoid receptor 2 (CB2) agonists have recently gained attention as potential therapeutic targets in the management of neuropathic pain. In this study, we characterized the pharmacological profile of the novel compound N′-[(3Z)-1-(1-hexyl)-2-oxo-1,2-dihydro-3H-indol-3- ylidene]benzohydrazide (MDA19), a CB2 agonist. METHODS: We used radioligand binding assays and multiple in vitro functional assays at human and rat CB1 and CB2 receptors. The effects of MDA19 in reversing neuropathic pain were assessed in various neuropathic pain models in rats and in CB2+/+ and CB2-/- mice. RESULTS: MDA19 displayed 4-fold-higher affinity at the human CB2 than at the human CB1 receptor (Ki = 43.3 ± 10.3 vs 162.4 ± 7.6 nM) and nearly 70-fold-higher affinity at the rat CB 2 than at the rat CB1 receptor (Ki = 16.3 ± 2.1 vs 1130 ± 574 nM). In guanosine triphosphate (GTP)γ[35S] functional assays, MDA19 behaved as an agonist at the human CB1 and CB2 receptors and at the rat CB 1 receptor but as an inverse agonist at the rat CB2 receptor. In 3′,5′-cyclic adenosine monophosphate (cAMP) assays, MDA19 behaved as an agonist at the rat CB1 receptor and exhibited no functional activity at the rat CB2 receptor. In extracellular signal-regulated kinases 1 and 2 activation assays, MDA19 behaved as an agonist at the rat CB2 receptor. MDA19 attenuated tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and CB2+/+ mice but not in CB2-/- mice, indicating that CB2 receptors mediated the effects of MDA19. MDA19 did not affect rat locomotor activity. CONCLUSIONS: We found that MDA19 exhibited a distinctive in vitro functional profile at rat CB2 receptors and behaved as a CB1/CB2 agonist in vivo, characteristics of a protean agonist. MDA19 has potential for alleviating neuropathic pain without producing adverse effects in the central nervous system.",
author = "Xu, {Jijun J.} and Philippe Diaz and Fanny Astruc-Diaz and Suzanne Craig and Elizandro Munoz and Mohamed Naguib",
year = "2010",
month = "7",
doi = "10.1213/ANE.0b013e3181e0cdaf",
language = "English (US)",
volume = "111",
pages = "99--109",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain

AU - Xu, Jijun J.

AU - Diaz, Philippe

AU - Astruc-Diaz, Fanny

AU - Craig, Suzanne

AU - Munoz, Elizandro

AU - Naguib, Mohamed

PY - 2010/7

Y1 - 2010/7

N2 - BACKGROUND: Cannabinoid receptor 2 (CB2) agonists have recently gained attention as potential therapeutic targets in the management of neuropathic pain. In this study, we characterized the pharmacological profile of the novel compound N′-[(3Z)-1-(1-hexyl)-2-oxo-1,2-dihydro-3H-indol-3- ylidene]benzohydrazide (MDA19), a CB2 agonist. METHODS: We used radioligand binding assays and multiple in vitro functional assays at human and rat CB1 and CB2 receptors. The effects of MDA19 in reversing neuropathic pain were assessed in various neuropathic pain models in rats and in CB2+/+ and CB2-/- mice. RESULTS: MDA19 displayed 4-fold-higher affinity at the human CB2 than at the human CB1 receptor (Ki = 43.3 ± 10.3 vs 162.4 ± 7.6 nM) and nearly 70-fold-higher affinity at the rat CB 2 than at the rat CB1 receptor (Ki = 16.3 ± 2.1 vs 1130 ± 574 nM). In guanosine triphosphate (GTP)γ[35S] functional assays, MDA19 behaved as an agonist at the human CB1 and CB2 receptors and at the rat CB 1 receptor but as an inverse agonist at the rat CB2 receptor. In 3′,5′-cyclic adenosine monophosphate (cAMP) assays, MDA19 behaved as an agonist at the rat CB1 receptor and exhibited no functional activity at the rat CB2 receptor. In extracellular signal-regulated kinases 1 and 2 activation assays, MDA19 behaved as an agonist at the rat CB2 receptor. MDA19 attenuated tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and CB2+/+ mice but not in CB2-/- mice, indicating that CB2 receptors mediated the effects of MDA19. MDA19 did not affect rat locomotor activity. CONCLUSIONS: We found that MDA19 exhibited a distinctive in vitro functional profile at rat CB2 receptors and behaved as a CB1/CB2 agonist in vivo, characteristics of a protean agonist. MDA19 has potential for alleviating neuropathic pain without producing adverse effects in the central nervous system.

AB - BACKGROUND: Cannabinoid receptor 2 (CB2) agonists have recently gained attention as potential therapeutic targets in the management of neuropathic pain. In this study, we characterized the pharmacological profile of the novel compound N′-[(3Z)-1-(1-hexyl)-2-oxo-1,2-dihydro-3H-indol-3- ylidene]benzohydrazide (MDA19), a CB2 agonist. METHODS: We used radioligand binding assays and multiple in vitro functional assays at human and rat CB1 and CB2 receptors. The effects of MDA19 in reversing neuropathic pain were assessed in various neuropathic pain models in rats and in CB2+/+ and CB2-/- mice. RESULTS: MDA19 displayed 4-fold-higher affinity at the human CB2 than at the human CB1 receptor (Ki = 43.3 ± 10.3 vs 162.4 ± 7.6 nM) and nearly 70-fold-higher affinity at the rat CB 2 than at the rat CB1 receptor (Ki = 16.3 ± 2.1 vs 1130 ± 574 nM). In guanosine triphosphate (GTP)γ[35S] functional assays, MDA19 behaved as an agonist at the human CB1 and CB2 receptors and at the rat CB 1 receptor but as an inverse agonist at the rat CB2 receptor. In 3′,5′-cyclic adenosine monophosphate (cAMP) assays, MDA19 behaved as an agonist at the rat CB1 receptor and exhibited no functional activity at the rat CB2 receptor. In extracellular signal-regulated kinases 1 and 2 activation assays, MDA19 behaved as an agonist at the rat CB2 receptor. MDA19 attenuated tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and CB2+/+ mice but not in CB2-/- mice, indicating that CB2 receptors mediated the effects of MDA19. MDA19 did not affect rat locomotor activity. CONCLUSIONS: We found that MDA19 exhibited a distinctive in vitro functional profile at rat CB2 receptors and behaved as a CB1/CB2 agonist in vivo, characteristics of a protean agonist. MDA19 has potential for alleviating neuropathic pain without producing adverse effects in the central nervous system.

UR - http://www.scopus.com/inward/record.url?scp=77954666488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954666488&partnerID=8YFLogxK

U2 - 10.1213/ANE.0b013e3181e0cdaf

DO - 10.1213/ANE.0b013e3181e0cdaf

M3 - Article

C2 - 20522703

AN - SCOPUS:77954666488

VL - 111

SP - 99

EP - 109

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 1

ER -